title: Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
abstract: Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were experiencing motor fluctuations with levodopa. Patients were randomly assigned to either drug or placebo in a 2:1 ratio in this double-blind, multicenter trial. Significant reductions in daily off time occurred at 4 to 6 weeks with the 1.25 mg dose (9.9%, P = 0.003) and 10 to 12 weeks with the 2.5 mg dose (13.2%, P < 0.001). The total number of off hours was reduced by 2.2 hours at Week 12 from baseline (compared with 0.6 hours in the placebo group). The average number of dyskinesia-free on hours for the Zydis selegiline patients increased by 1.8 hours at Week 12. There was no change in mean percentage of "Asleep" time throughout the study. No apparent differences were detected in the occurrence of drug-related adverse events between the Zydis selegiline group and placebo-treated groups. Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD.
authors.affiliation: Department of Neurology, Columbia University, New York, New York 10032, USA. cw345@columbia.edu
authors.forename: Cheryl H
authors.initials: CH
authors.lastname: Waters
authors.forename: Kapil D
authors.initials: KD
authors.lastname: Sethi
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hauser
authors.forename: Eric
authors.initials: E
authors.lastname: Molho
authors.forename: John M
authors.initials: JM
authors.lastname: Bertoni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*; D012642:Selegiline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012720:Severity of Illness Index
chemical_list: D000978:Antiparkinson Agents; D012642:Selegiline